ASH 2023 | Risk of transformation by frontline management in FL and MZL: a US population-based analysis
Juan Alderuccio, MD, Sylvester Comprehensive Cancer Center, Miami, FL, comments on a US population-based analysis of incidence and risk factors for high-grade transformation (HGT) in patients with follicular lymphoma (FL) or subtypes of marginal zone lymphoma (MZL) (splenic, nodal, and extranodal), with either surveillance or treatment as initial strategies. Outcomes varied between these malignancies, with the risk of HGT into diffuse large B cell lymphoma (DLBCL) and overall survival (OS) post-HGT differing depending on whether frontline treatment was administered. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: Genmab, ADC Therapeutics, BeiGene
Consultancy: Abbvie, ADC Therapeutics, Genentech, Regeneron
